These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16410717)

  • 1. Detection of BRAF gene mutation in primary choroidal melanoma tissue.
    Malaponte G; Libra M; Gangemi P; Bevelacqua V; Mangano K; D'Amico F; Mazzarino MC; Stivala F; McCubrey JA; Travali S
    Cancer Biol Ther; 2006 Feb; 5(2):225-7. PubMed ID: 16410717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF somatic mutations in malignant melanoma and melanocytic naevi.
    Thomas NE
    Melanoma Res; 2006 Apr; 16(2):97-103. PubMed ID: 16567964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway.
    Calipel A; Lefevre G; Pouponnot C; Mouriaux F; Eychène A; Mascarelli F
    J Biol Chem; 2003 Oct; 278(43):42409-18. PubMed ID: 12917419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
    Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
    Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
    Maat W; Kilic E; Luyten GP; de Klein A; Jager MJ; Gruis NA; Van der Velden PA
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.
    Zuidervaart W; van Nieuwpoort F; Stark M; Dijkman R; Packer L; Borgstein AM; Pavey S; van der Velden P; Out C; Jager MJ; Hayward NK; Gruis NA
    Br J Cancer; 2005 Jun; 92(11):2032-8. PubMed ID: 15928660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The T1799A point mutation is present in posterior uveal melanoma.
    Janssen CS; Sibbett R; Henriquez FL; McKay IC; Kemp EG; Roberts F
    Br J Cancer; 2008 Nov; 99(10):1673-7. PubMed ID: 18985043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
    Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
    Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
    Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
    Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
    Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of BRAF mutation and extracellular regulated protein kinases activation in nasal mucosa melanomas].
    Li HY; Zhou L; Tian J; Cong N
    Zhonghua Yi Xue Za Zhi; 2010 Dec; 90(48):3399-402. PubMed ID: 21223812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
    Fan F; Feng L; He J; Wang X; Jiang X; Zhang Y; Wang Z; Chen Y
    Carcinogenesis; 2008 Jun; 29(6):1157-63. PubMed ID: 18515281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of BRAF mutations in uveal melanoma.
    Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
    Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
    Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
    J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.
    Greaves WO; Verma S; Patel KP; Davies MA; Barkoh BA; Galbincea JM; Yao H; Lazar AJ; Aldape KD; Medeiros LJ; Luthra R
    J Mol Diagn; 2013 Mar; 15(2):220-6. PubMed ID: 23273605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
    Yazdi AS; Ghoreschi K; Sander CA; Röcken M
    Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
    Yang H; Higgins B; Kolinsky K; Packman K; Go Z; Iyer R; Kolis S; Zhao S; Lee R; Grippo JF; Schostack K; Simcox ME; Heimbrook D; Bollag G; Su F
    Cancer Res; 2010 Jul; 70(13):5518-27. PubMed ID: 20551065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.